摘要
目的 评估非亲缘和亲缘供者异基因骨髓移植治疗骨髓增生异常综合征 (MDS)的临床疗效。方法 对 2例MDS 难治性贫血、MDS 原始细胞增多伴转化型患者分别进行非亲缘和亲缘供髓的异基因骨髓移植术。 2例均为男性 ,年龄 17和 2 0岁。预处理为马利兰和环磷酰胺化疗方案。以霉酚酸酯加环孢素A和短程氨甲蝶呤预防移植物抗宿主病 ,低剂量肝素和前列腺素E1脂质微球预防肝静脉阻塞病。结果 2例患者骨髓移植后的中性粒细胞数 ( >0 .5× 10 9/L)分别在第 2 1和第 17天。移植后无病生存已分别为 10个月和 3个半月。经DNA短串联重复序列多态性分析和染色体检查 ,均为供者骨髓植活。结论 本研究为非亲缘异基因骨髓移植治疗MDS国内首篇报道 ,非亲缘和亲缘供者异基因骨髓移植术是治疗MDS的有效方法。
Objective To study on allogeneic bone marrow transplantation (BMT) with unrelated donor or sibling donor for myelodysplastic syndrome-refractory anemia and myelodysplastic syndrome-refractory anemia with excess blasts in transformation patients. Methods Two male patients received chemotherapy regimen of busulfan-cyclophosphamide before allogeneic BMT. Mycophenolate mofetil combined with cyclosporin A and methotrexate was used for prevention of acute graft-versus-host disease after transplantation. Low dose heparin and lipo prostaglandin E 1 were used in prophylactic regimen for hepatic veno-occlusive disease. Results Neutrophil count began to be higher than 0.5×109/L on 21st and 17th days after BMT in the two patients. Disease-free survival in the two patients was 10 months and 3.5 months respectively. Conclusion Allogeneic bone marrow transplantation with unrelated or sibling donor is an effective therapy for patients with MDS.
出处
《中华内科杂志》
CAS
CSCD
北大核心
2000年第10期664-666,共3页
Chinese Journal of Internal Medicine
关键词
骨髓增生异常综合征
骨髓移植
组织供者
Myelodysplastic syndromes
Bone marrow transplantation
Tissue donors
Sibling relations
